Pyzchiva Receives FDA Approval as Third Ustekinumab BiosimilarJuly 2, 2024Psoriatic ArthritisPediatrics
Psoriatic Arthritis Symptoms Relieved with TYK2 Inhibitor in Phase 2 TrialJune 28, 2024Psoriatic Arthritis
Psoriatic Arthritis Drug Candidate Sonelokimab Yields Significant Improvements in Phase 2 TrialJune 28, 2024Psoriatic Arthritis
What’s in a Name: Defining Difficult-to-Treat axSpA and PsAJune 14, 2024SpondyloarthropathiesAnkylosing spondylitisPsoriatic Arthritis
EULAR 2024 Preview: Therapeutics in Development Take Center StageJune 11, 2024Rheumatoid ArthritisPsoriatic ArthritisPediatricsOsteoarthritisLupus & Connective Tissue Diseases
Clear Coverage Preference for Humira Over Biosimilars Seen in Most Medicare Part D PlansJune 7, 2024Business of MedicineRheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisAnkylosing spondylitis
Over-the-Counter Arthritis Supplements Pose Adrenal DangerJune 6, 2024OsteoporosisOsteoarthritisRheumatoid ArthritisPsoriatic Arthritis
Study Finds Mace Risk Remains High in Patients with Psoriasis, DyslipidemiaJune 4, 2024Psoriatic Arthritis
Cortisol Test Confirms HPA Axis Recovery from Steroid UseMay 28, 2024Rheumatoid ArthritisLupus & Connective Tissue DiseasesPsoriatic ArthritisPediatrics
Recent Evidence for Home Phototherapy Benefits May Improve Access for Patients with PsoriasisMay 23, 2024Psoriatic Arthritis
Specialists Are ‘Underwater’ With Some Insurance-Preferred BiosimilarsMay 16, 2024Business of MedicineRheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisAnkylosing spondylitisLupus & Connective Tissue Diseases
Poor Use of ICD-10 Rheumatology Codes Suggests New Approach Needed for ICD-11 AdoptionApril 26, 2024Rheumatoid ArthritisPsoriatic ArthritisAnkylosing spondylitisSpondyloarthropathiesBusiness of Medicine
Combined Pediatric Derm-Rheum Clinics Supported by Survey RespondentsApril 22, 2024PediatricsPsoriatic ArthritisSpondyloarthropathiesLupus & Connective Tissue DiseasesBusiness of Medicine
